Chugai Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Chugai Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chugai Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chugai Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Roche Holding AG, specializes in biotechnological research and drug manufacturing. The company manufactures, markets, exports and imports pharmaceutical products in Japan and other countries. The company offers products for the treatment of various therapeutic areas including, oncology, immunology, ophthalmology, hematology, neuroscience; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe, and Asia. Chugai is headquartered in Chuo-ku, Tokyo, Japan.
Headquarters
Japan
Address
1-1 Nihonbashi-Muromachi 2-chome, 12th Floor, Nihonbashi Mitsui Tower, Chuo-Ku, Tokyo, 103-8324
Website
www.chugai-pharm.co.jp
Telephone
81 3 32816611
No of Employees
7,872
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4519 (TYO)
Revenue (2024)
$8.1B
7.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
12.1%
(2024 vs 2023)
Market Cap*
$63.8B
Net Profit Margin (2024)
XYZ
4.3%
(2024 vs 2023)
* As of and is in US$
Chugai Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Marketed | Actemra |
| Oncology: | Avastin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Plans/Strategy | In September, the company announced its plans to open Chugai Pharma Korea Co., Ltd. |
| 2026 | Regulatory Approval | In September, the company secured approval from the Ministry of Health, Labour and Welfare for FoundationOne CDx Cancer Genomic Profile to be used as a companion diagnostic for Pfizer Japan Inc’s third-generation ALK inhibitor, LORBRENA tablets 25 mg and 100 mg. |
| 2026 | Contracts/Agreements | In August, the company signed a license agreement with GSK for the anti-dengue virus antibody, AID351. |
Competitor Comparison
| Key Parameters | Chugai Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Shionogi & Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chuo-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
| No. of Employees | 7,872 | 47,029 | 14,099 | 20,171 | 6,223 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Osamu Okuda | Chief Executive Officer; Head- Audit Department; Director; President | Executive Board | 2021 | 62 |
| Iwaaki Taniguchi | Executive Vice President; Corporate Planning Dept.; Chief Financial Officer; Director | Executive Board | 2024 | 59 |
| Hitoshi Iikura | Corporate Planning Dept.; Director; Executive Vice President | Executive Board | 2024 | 55 |
| Shinji Hidaka | Executive Vice President - Marketing & Sales, Drug Safety, Medical Affairs; Executive Vice President - PHC Solution and Special Mission for Overseas Marketing | Senior Management | - | - |
| Kaori Ouchi | Executive Vice President - Quality & Regulatory Compliance; Executive Vice President - Pharmaceutical Technology and Manufacturing Technology | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer